Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prescription Drugs | 25 | 2024 | 630 | 10.060 |
Why?
|
Drug Costs | 38 | 2024 | 1185 | 9.340 |
Why?
|
Drugs, Generic | 22 | 2024 | 448 | 7.900 |
Why?
|
Drug Approval | 15 | 2024 | 816 | 4.110 |
Why?
|
Medicare Part D | 12 | 2024 | 354 | 3.460 |
Why?
|
Drug Industry | 14 | 2024 | 789 | 3.130 |
Why?
|
Medicaid | 13 | 2024 | 2815 | 3.010 |
Why?
|
Pharmacy | 3 | 2024 | 92 | 2.410 |
Why?
|
Pharmacies | 4 | 2024 | 164 | 1.980 |
Why?
|
Economic Competition | 6 | 2024 | 218 | 1.950 |
Why?
|
Orphan Drug Production | 3 | 2024 | 48 | 1.900 |
Why?
|
Inflation, Economic | 2 | 2023 | 28 | 1.750 |
Why?
|
Medicare Part B | 3 | 2023 | 117 | 1.740 |
Why?
|
United States | 68 | 2024 | 72461 | 1.510 |
Why?
|
Cost Savings | 4 | 2024 | 920 | 1.460 |
Why?
|
Anti-Obesity Agents | 2 | 2024 | 229 | 1.450 |
Why?
|
Medicare | 14 | 2024 | 6786 | 1.390 |
Why?
|
United States Food and Drug Administration | 11 | 2024 | 1677 | 1.340 |
Why?
|
Health Expenditures | 10 | 2024 | 2362 | 1.120 |
Why?
|
Negotiating | 5 | 2024 | 148 | 1.010 |
Why?
|
Pharmaceutical Services | 2 | 2024 | 141 | 1.010 |
Why?
|
Off-Label Use | 2 | 2024 | 184 | 0.990 |
Why?
|
Drug Labeling | 3 | 2024 | 251 | 0.970 |
Why?
|
Federal Government | 2 | 2023 | 267 | 0.950 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2023 | 345 | 0.900 |
Why?
|
Hiccup | 1 | 2023 | 8 | 0.890 |
Why?
|
Device Approval | 3 | 2014 | 165 | 0.880 |
Why?
|
Legislation, Drug | 3 | 2023 | 214 | 0.870 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2024 | 385 | 0.870 |
Why?
|
Policy | 2 | 2024 | 511 | 0.860 |
Why?
|
Citric Acid | 1 | 2023 | 123 | 0.840 |
Why?
|
Drug Substitution | 2 | 2022 | 296 | 0.780 |
Why?
|
Deductibles and Coinsurance | 2 | 2021 | 316 | 0.770 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 49 | 0.750 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2024 | 268 | 0.750 |
Why?
|
Vasopressins | 1 | 2022 | 355 | 0.740 |
Why?
|
Commerce | 2 | 2023 | 605 | 0.730 |
Why?
|
Immunization Schedule | 1 | 2021 | 224 | 0.710 |
Why?
|
Hydroxychloroquine | 2 | 2021 | 427 | 0.710 |
Why?
|
Anti-Asthmatic Agents | 1 | 2024 | 565 | 0.670 |
Why?
|
Herpes Zoster | 1 | 2021 | 251 | 0.650 |
Why?
|
Drug Evaluation | 1 | 2020 | 641 | 0.630 |
Why?
|
Marketing | 5 | 2024 | 220 | 0.630 |
Why?
|
Drug Utilization | 2 | 2021 | 1195 | 0.610 |
Why?
|
Abortion, Induced | 1 | 2023 | 460 | 0.590 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13630 | 0.570 |
Why?
|
Multiple Sclerosis | 2 | 2024 | 3204 | 0.570 |
Why?
|
Humans | 80 | 2024 | 760621 | 0.560 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 685 | 0.560 |
Why?
|
Costs and Cost Analysis | 5 | 2024 | 1677 | 0.550 |
Why?
|
Quality-Adjusted Life Years | 1 | 2023 | 1724 | 0.540 |
Why?
|
Insurance Coverage | 3 | 2024 | 1939 | 0.540 |
Why?
|
Motivation | 2 | 2023 | 1993 | 0.520 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2022 | 615 | 0.520 |
Why?
|
Psoriasis | 1 | 2024 | 940 | 0.510 |
Why?
|
Hepatitis C, Chronic | 1 | 2024 | 1031 | 0.510 |
Why?
|
Anti-Infective Agents | 1 | 2023 | 981 | 0.510 |
Why?
|
Vaccines | 1 | 2024 | 832 | 0.500 |
Why?
|
Cross-Sectional Studies | 12 | 2024 | 25942 | 0.480 |
Why?
|
Patents as Topic | 3 | 2024 | 112 | 0.470 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7408 | 0.460 |
Why?
|
Influenza Vaccines | 1 | 2021 | 766 | 0.460 |
Why?
|
Defibrillators, Implantable | 2 | 2014 | 1499 | 0.460 |
Why?
|
Hepatitis C | 1 | 2024 | 1579 | 0.450 |
Why?
|
Antirheumatic Agents | 1 | 2023 | 1374 | 0.440 |
Why?
|
Health Care Reform | 1 | 2022 | 1245 | 0.430 |
Why?
|
Biological Factors | 2 | 2024 | 157 | 0.420 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2803 | 0.410 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2014 | 452 | 0.410 |
Why?
|
Medication Adherence | 2 | 2021 | 2165 | 0.410 |
Why?
|
Insulin | 2 | 2023 | 6597 | 0.370 |
Why?
|
State Government | 2 | 2024 | 380 | 0.370 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5397 | 0.370 |
Why?
|
Pharmaceutical Preparations | 3 | 2024 | 1091 | 0.360 |
Why?
|
Osteoarthritis, Knee | 7 | 2014 | 1234 | 0.360 |
Why?
|
Prescription Fees | 2 | 2022 | 151 | 0.360 |
Why?
|
Influenza, Human | 1 | 2021 | 1528 | 0.350 |
Why?
|
Prescriptions | 2 | 2022 | 388 | 0.340 |
Why?
|
France | 3 | 2024 | 511 | 0.300 |
Why?
|
Pacemaker, Artificial | 1 | 2014 | 815 | 0.300 |
Why?
|
Medicare Part C | 2 | 2024 | 322 | 0.290 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4166 | 0.290 |
Why?
|
Aged | 21 | 2024 | 169152 | 0.270 |
Why?
|
Insurance Claim Review | 2 | 2021 | 738 | 0.270 |
Why?
|
Neoplasms | 3 | 2023 | 22072 | 0.260 |
Why?
|
Hospitals | 1 | 2019 | 3928 | 0.260 |
Why?
|
Arthroplasty, Replacement, Knee | 5 | 2014 | 1370 | 0.260 |
Why?
|
Asthma | 1 | 2024 | 6172 | 0.250 |
Why?
|
Rare Diseases | 2 | 2024 | 619 | 0.250 |
Why?
|
Heart Valve Prosthesis | 1 | 2014 | 1495 | 0.240 |
Why?
|
Time Factors | 9 | 2024 | 40165 | 0.230 |
Why?
|
Databases, Factual | 4 | 2024 | 8035 | 0.220 |
Why?
|
Legislation as Topic | 1 | 2023 | 77 | 0.220 |
Why?
|
Citrates | 1 | 2023 | 135 | 0.210 |
Why?
|
Catechols | 1 | 2022 | 62 | 0.210 |
Why?
|
Equipment Safety | 2 | 2014 | 253 | 0.210 |
Why?
|
Biological Therapy | 1 | 2024 | 139 | 0.210 |
Why?
|
Mifepristone | 1 | 2023 | 150 | 0.210 |
Why?
|
Burnout, Professional | 2 | 2022 | 702 | 0.210 |
Why?
|
Antisocial Personality Disorder | 1 | 2023 | 224 | 0.210 |
Why?
|
Cardiology | 1 | 2014 | 1723 | 0.200 |
Why?
|
Cohort Studies | 6 | 2024 | 41335 | 0.200 |
Why?
|
European Union | 1 | 2023 | 157 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.200 |
Why?
|
Electronic Health Records | 1 | 2019 | 4775 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
Atrial Fibrillation | 1 | 2021 | 5209 | 0.200 |
Why?
|
Pharmacy Service, Hospital | 1 | 2022 | 135 | 0.180 |
Why?
|
Australia | 1 | 2024 | 1289 | 0.180 |
Why?
|
Pharmacists | 1 | 2022 | 259 | 0.170 |
Why?
|
National Health Programs | 1 | 2023 | 441 | 0.170 |
Why?
|
Knee Prosthesis | 2 | 2013 | 394 | 0.170 |
Why?
|
Reimbursement, Incentive | 1 | 2024 | 542 | 0.160 |
Why?
|
Cost Control | 1 | 2021 | 630 | 0.160 |
Why?
|
Chloroquine | 1 | 2020 | 277 | 0.160 |
Why?
|
Stroke | 1 | 2021 | 9962 | 0.150 |
Why?
|
Drugs, Investigational | 1 | 2020 | 214 | 0.150 |
Why?
|
Antithrombins | 1 | 2021 | 313 | 0.150 |
Why?
|
Policy Making | 1 | 2021 | 538 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.150 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15757 | 0.150 |
Why?
|
Cost Sharing | 1 | 2021 | 410 | 0.150 |
Why?
|
Pandemics | 3 | 2023 | 8624 | 0.150 |
Why?
|
Sample Size | 1 | 2021 | 840 | 0.140 |
Why?
|
Nitriles | 1 | 2022 | 956 | 0.140 |
Why?
|
California | 1 | 2021 | 1416 | 0.140 |
Why?
|
Hepacivirus | 1 | 2024 | 1334 | 0.140 |
Why?
|
Government Regulation | 1 | 2021 | 525 | 0.140 |
Why?
|
HIV Infections | 1 | 2023 | 17165 | 0.130 |
Why?
|
Pyridones | 1 | 2021 | 792 | 0.130 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 919 | 0.120 |
Why?
|
Disclosure | 1 | 2021 | 738 | 0.120 |
Why?
|
Physicians, Women | 1 | 2020 | 495 | 0.120 |
Why?
|
Drug Prescriptions | 2 | 2021 | 1673 | 0.120 |
Why?
|
Biological Products | 1 | 2023 | 916 | 0.120 |
Why?
|
Medicine | 1 | 2022 | 943 | 0.110 |
Why?
|
Consensus | 1 | 2023 | 3113 | 0.110 |
Why?
|
Female | 15 | 2024 | 391270 | 0.110 |
Why?
|
Thiazoles | 1 | 2021 | 1511 | 0.110 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 1779 | 0.110 |
Why?
|
Male | 14 | 2024 | 359744 | 0.100 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8056 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4899 | 0.100 |
Why?
|
Warfarin | 1 | 2021 | 1518 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1386 | 0.100 |
Why?
|
Middle Aged | 12 | 2024 | 220352 | 0.100 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 5508 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1628 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2024 | 3061 | 0.100 |
Why?
|
Internship and Residency | 2 | 2022 | 5870 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 1999 | 0.090 |
Why?
|
Adult | 8 | 2024 | 219994 | 0.090 |
Why?
|
Prosthesis Failure | 2 | 2013 | 1206 | 0.080 |
Why?
|
Physical Therapy Modalities | 1 | 2013 | 536 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2754 | 0.080 |
Why?
|
Double-Blind Method | 1 | 2023 | 12427 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2879 | 0.080 |
Why?
|
Range of Motion, Articular | 1 | 2014 | 1583 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3150 | 0.070 |
Why?
|
Postoperative Care | 1 | 2013 | 1479 | 0.070 |
Why?
|
Obesity | 2 | 2024 | 12922 | 0.070 |
Why?
|
Adolescent | 3 | 2024 | 87810 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9185 | 0.070 |
Why?
|
Longevity | 1 | 2013 | 1050 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3527 | 0.060 |
Why?
|
Anticoagulants | 1 | 2021 | 4897 | 0.060 |
Why?
|
Life Expectancy | 1 | 2011 | 1248 | 0.060 |
Why?
|
Infant, Newborn | 1 | 2024 | 26181 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4591 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3388 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58995 | 0.050 |
Why?
|
Pain, Postoperative | 1 | 2013 | 1721 | 0.050 |
Why?
|
Infant | 1 | 2024 | 36060 | 0.050 |
Why?
|
Pregnancy | 1 | 2023 | 29749 | 0.050 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2021 | 36 | 0.050 |
Why?
|
Child, Preschool | 1 | 2024 | 42063 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5889 | 0.050 |
Why?
|
Investments | 1 | 2023 | 148 | 0.050 |
Why?
|
Germany | 1 | 2023 | 873 | 0.050 |
Why?
|
Formularies as Topic | 1 | 2020 | 93 | 0.040 |
Why?
|
New York | 1 | 2021 | 875 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2021 | 597 | 0.040 |
Why?
|
Insurance Benefits | 1 | 2020 | 191 | 0.040 |
Why?
|
Young Adult | 1 | 2024 | 58741 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2128 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 6180 | 0.040 |
Why?
|
Models, Statistical | 1 | 2011 | 5075 | 0.030 |
Why?
|
Risk Assessment | 2 | 2019 | 24123 | 0.030 |
Why?
|
Uncertainty | 1 | 2021 | 754 | 0.030 |
Why?
|
Child | 1 | 2024 | 79806 | 0.030 |
Why?
|
Hospital Costs | 1 | 2022 | 976 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11847 | 0.030 |
Why?
|
Boston | 2 | 2019 | 9280 | 0.030 |
Why?
|
Pain Measurement | 2 | 2013 | 3528 | 0.030 |
Why?
|
Recovery of Function | 2 | 2013 | 2985 | 0.030 |
Why?
|
Reoperation | 2 | 2013 | 4291 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 422 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8552 | 0.020 |
Why?
|
Age Factors | 3 | 2013 | 18416 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6828 | 0.020 |
Why?
|
Menisci, Tibial | 1 | 2013 | 269 | 0.020 |
Why?
|
Telephone | 1 | 2013 | 624 | 0.020 |
Why?
|
Risk | 2 | 2013 | 9631 | 0.020 |
Why?
|
Models, Economic | 1 | 2013 | 719 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8803 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 80372 | 0.020 |
Why?
|
Research | 1 | 2017 | 1974 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14660 | 0.020 |
Why?
|
Knee Injuries | 1 | 2013 | 489 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1830 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2023 | 12766 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2581 | 0.020 |
Why?
|
Sex Distribution | 1 | 2013 | 2295 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2893 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2648 | 0.020 |
Why?
|
Knee Joint | 1 | 2014 | 1663 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3323 | 0.020 |
Why?
|
Orthopedics | 1 | 2014 | 892 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2019 | 65017 | 0.020 |
Why?
|
Cost of Illness | 1 | 2013 | 1940 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3711 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3448 | 0.010 |
Why?
|
Health Care Costs | 1 | 2013 | 3258 | 0.010 |
Why?
|
Risk Factors | 2 | 2019 | 74359 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6218 | 0.010 |
Why?
|
Quality Improvement | 1 | 2013 | 3836 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10551 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14495 | 0.010 |
Why?
|
Models, Biological | 1 | 2013 | 9467 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13502 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15840 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15687 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 21392 | 0.010 |
Why?
|
Quality of Life | 1 | 2013 | 13308 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15697 | 0.010 |
Why?
|
Prospective Studies | 1 | 2014 | 54303 | 0.010 |
Why?
|
Concepts
(236)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(75)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_